Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725803 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00725803 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 33 participants.
The verdict
NCT00725803, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Hepatitis C Virus (HCV) infection.
Interventions
- DRUG GS-9450
- DRUG GS-9450 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725803
The ClinicalTrials.gov registry entry for NCT00725803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GS-9450 is the first listed.
NCT00725803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725803 about?
NCT00725803 is a clinical study titled "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV". The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Hepatitis C Virus (HCV) infection.
What is the current status of trial NCT00725803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2008-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00725803?
The interventions under investigation include: GS-9450 (DRUG), GS-9450 Placebo (DRUG).
Who is sponsoring clinical trial NCT00725803?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.